P&G Portfolio Trimming ‘Full Steam Ahead’ As Currency Headwind Pummels Profit
This article was originally published in The Tan Sheet
P&G’s net income declined 31% in its second quarter and will decline for its full fiscal 2015 due to foreign exchange, but the firm remains focused on core brand growth and innovation and will weather the storm. The company so far sold or consolidated 35 of the 90 to 100 brands on its streamlining chopping block.
You may also be interested in...
Marketing exclusivity would be a key advantage as Nexium 24HR enters a crowded market of branded and private label OTC competitors. The NDA for Nexium 24HR included clinical data, Pfizer says, but whether FDA allowed Hatch-Waxman Act exclusivity for the product is not yet determined.
The mega-retailer is defending a proposed class action in Minnesota federal court over its ‘Target Clean’ marketing and label, which it has awarded "independently" to around 4,000 products in its stores. Consumer plaintiffs allege some offerings contain ingredients on the program's “formulated without” list, as well as other hazardous substances that ought not be in clean products. Pending litigation against Sephora stands to be influential.
FDA introduces Cosmetics Direct for registering manufacturing facilities and listing products, a little more than three months from registration deadlines set by new cosmetics regulations, and provides looks at the forms companies will need to submit. For now at least, the 29 December deadlines stand, notwithstanding stakeholder pressure for extensions or enforcement discretion.